This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management.
Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today’s available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.
|Author||: Benjamin Bonavida|
|Publisher||: Springer Science & Business Media|
|Release Date||: 2013-08-04|
|ISBN 10||: 1461476542|
|Pages||: 202 pages|
The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can bind only to cancer cell-specific antigens and induce an immunological response against the target cancer cell. The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.
Lewis's Medical-Surgical Nursing ANZ 5th edition continues as the most comprehensive, go-to reference for developing the core aspects of professional nursing care in Australia and New Zealand. With a clear framework of person-centred care, critical thinking, clinical reasoning and evidence-based practice underpinning the assessment and management of adults with complex, acute and chronic healthcare issues, the 5th edition provides nursing students with the foundations for developing expert clinical practice. Thoroughly revised, the new edition responds to key health priorities, providing an innovative approach to addressing Indigenous health in Australia and New Zealand. Greater emphasis is also given to the issues of: self-care; examination of the nurse's role within an interprofessional team; and management of the deteriorating patient, to reflect the changing nature of nursing practice in the contemporary healthcare environment. Additional resources on Evolve eBook on VitalSource Student and Instructor Resources Review Questions Conceptual Care Map creator Student Case studies Fluids and Electrolytes tutorial Nursing Care Plans Instructor Resources Test Bank PowerPoint slides Image bank Now available in either hard cover or 2-volume set paperback formats New chapters: Chapter 3: Stress and coping. This chapter explores theoretical models of stress, the impact of stress on human functioning, and strategies for coping with stress in the context of nursing practice and healthcare delivery Chapter 5: Working with Indigenous peoples of Australia and New Zealand. Co-authored by highly respected Indigenous and non-Indigenous academics from Australia and New Zealand, the chapter role-models Indigenous and non-Indigenous health professionals working alongside each other to improve health outcomes, and the practical role that nurses can play to improve the healthcare experiences of Indigenous people. Chapter 69: Recognising and responding to the deteriorating patient. Authored by one of Australia's leaders in emergency response education, this chapter is designed to develop capability in relation to the National Safety and Quality Health Service Standards 2017, specifically Standard 8: Recognising and responding to acute deterioration. Chapter 70: Cardiopulmonary resuscitation: basic and advanced life support. Based on the Australian and New Zealand Committee on Resuscitation (ANZCOR) guidelines, this chapter promotes a problem-solving approach to the management of a patient in cardiac arrest by providing the science behind the techniques and interventions used to treat a patient in cardiac arrest.
The Ninth Annual Pezcoller Symposium entitled "The Biology of Tumors" was held in Rovereto, Italy, June 4-7, 1997. It focused on the genetic mechanisms underlying het erogeneity of tumor cell populations and tumor cell differentiation, on interactions be tween tumor cells and cells of host defenses, and the mechanisms of angiogenesis. With presentations at the cutting edge of progress and stimulating discussions, this symposium addressed issues related to phenomena concerned with cell regulation and cell interactions as determined by activated genes through the appropriate and timely media tion of gene products. Important methodologies that would allow scientists to measure dif ferentially genes and gene products and thus validate many of the mechanisms of control currently proposed were considered, as were the molecular basis of tumor recognition by the immune system, interactions between cells and molecular mechanisms of cell regula tion as they are affected by or implemented through these interactions. The molecular and cellular mechanisms of tumor vascularization were also discussed. It was recognized that angiogenesis provides a potential site of therapeutic intervention and this makes it even more important to understand the mechanisms underlying it. We wish to thank the participants in the symposium for their substantial contribu tions and their participation in the spirited discussions that followed. We would also like to thank Drs.
Leading experts summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to anticancer drugs, and suggest new approaches to preventing and overcoming it. The authors review physiological resistance based upon tumor architecture, cellular resistance based on drug transport, epigenetic changes that neutralize or bypass drug cytotoxicity, and genetic changes that alter drug target molecules by decreasing or eliminating drug binding and efficacy. Highlights include new insights into resistance to antiangiogenic therapies, oncogenes and tumor suppressor genes in therapeutic resistance, cancer stem cells, and the development of more effective therapies. There are also new findings on tumor immune escape mechanisms, gene amplification in drug resistance, the molecular determinants of multidrug resistance, and resistance to taxanes and Herceptin.
Despite recent advances in adjuvant therapies of cancer, the regi mens of postoperative adjuvant chemotherapy treatment which are presently available fail to cure the majority of cancer patients. Pre operative (neoadjuvant) chemotherapy represents a new approach in drug scheduling, based on sound theoretical, pharmacokinetic, and experimental principles. The preoperative timing of chemotherapy before definitive sur gery is not a minor change in the therapy of cancer. To be successful, large numbers of practitioners and their patients must participate. Substantial alterations of many aspects of the present management of cancer will have to follow. Therefore, before such therapy can be fully and routinely implemented, results of the novel treatment and its rationale have to be carefully evaluated. In preoperative treatment, other features will likely gain impor tance. For the first time, clinicians have a chance to follow the in vivo response of the tumor exposed to preoperative chemotherapy. The subsequent histological assessment of the tumor sample may likely become an important prognostic guide, permitting more re fined individual approaches to the planning of postoperative adju vant treatment. The value of such a treatment strategy can already be appreciated in the clinical setting, as seen from the therapy of osteosarcoma. Furthermore, preoperative chemotherapy might render previously inoperable tumors operable and hence resectable with a curative intention. The preoperative reduction of tumor bulk may also effectively decrease the need for more radical operations, permitting a more uniform adoption of conservative surgery.
In Breast Cancer Chemosensitivity, a group of world leading experts review critical aspects of resistance to systemic therapy in breast cancer patients. Beginning with a clinical overview of the problem, the book then focuses on the latest findings of molecular mechanisms of drug resistance. Coverage provides an example of using novel approaches for chemosensitization of breast cancer cells that gives readers an idea about the future direction in breast cancer treatment. It allows those who are interested in breast cancer therapy to get a jump-start on critical issues in breast cancer therapeutic resistance.